ProQR Therapeutics (PRQR) Total Current Liabilities (2013 - 2026)

ProQR Therapeutics has reported Total Current Liabilities for 14 years, with the latest figure at $41.0 million in Q1 2026.

• Quarterly Total Current Liabilities rose 15.73% year-over-year to $41.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $41.0 million (up 15.73% YoY) and the FY2025 annual result came in at $37.8 million, down 9.16% from the prior year.
• Total Current Liabilities rose to $41.0 million in Q1 2026 per PRQR's latest filing, from $37.8 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $43.5 million in Q3 2024 and troughed at $18.4 million in Q1 2023.
• A 5-year average of $33.3 million and a median of $36.8 million in 2023 frame the typical range for Total Current Liabilities.
• The widest YoY moves for Total Current Liabilities: up 210168.06% in 2022, down 33.52% in 2022.
• Over 5 years, Total Current Liabilities stood at $21.4 million in 2022, then soared by 71.86% to $36.8 million in 2023, then climbed by 12.96% to $41.6 million in 2024, then fell by 9.16% to $37.8 million in 2025, then increased by 8.69% to $41.0 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $41.0 million, $37.8 million, and $38.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.